论文部分内容阅读
目的分析研讨依达拉奉联合疏血通治疗老年脑梗死患者疗效。方法本次讨论中所研讨的76例患者均随机从我院2015年10月至2016年9月期间接收的老年脑梗死患者中筛选而出,将其随机分两组,38例对照组(接受疏血通治疗)和38例研究组(接受依达拉奉与疏血通联合治疗),将两组患者治疗效果纳入对比研讨中。结果研究组患者的临床总有效率92.11%比对照组71.05%高,组间数据有统计学意义(P<0.05);研究组患者不良反应发生率7.89%比对照组18.42%低,组间数据有统计学意义(P<0.05)。结论采取依达拉奉与疏血通联合治疗老年脑梗死患者,其疗效显著,不良反应少,安全性高,临床应用及推广价值大。
Objective To study the therapeutic effect of edaravone combined with Shuxuetong on senile patients with cerebral infarction. Methods All the 76 patients studied in this study were randomly selected from elderly patients with cerebral infarction received from our hospital from October 2015 to September 2016. They were randomly divided into two groups and 38 control subjects Shuxuetong treatment) and 38 cases of study group (receiving edaravone and Shuxuetong combination therapy), the treatment effect of both groups included in the comparative study. Results The total clinical effective rate in study group was 92.11% higher than 71.05% in control group (P <0.05). The incidence of adverse reactions in study group was 7.89% lower than that in control group (18.42%). Intergroup data There was statistical significance (P <0.05). Conclusion Edaravone and Shuxuetong combined treatment of elderly patients with cerebral infarction, the effect was significant, fewer adverse reactions, high safety, clinical application and promotion of great value.